|
[1] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.
|
|
[2] CHARLTON MR,BURNS JM,PEDERSEN RA,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the united states[J]. Gastroenterology,2011,141(4):1249-1253.
|
|
[3] STINE JG,SHAH NL,ARGO CK,et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis[J]. Liver Transpl,2015,21(8):1016-1021.
|
|
[4] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.
|
|
[5] FAN JG,KIM SU,WONG VW. New trends on obesity and nafld in asia[J]. J Hepatol,2017,67(4):862-873.
|
|
[6] LI SP,WANG QC. Progress of the epidemiology of non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol,2017,26(10):1085-1087.(in Chinese)李生鹏，王全楚．非酒精性脂肪性肝病的流行病学进展[J]．胃肠病学和肝病学杂志，2017,26(10):1085-1087.
|
|
[7] KHASPEKOVA SG,ZIURIAEV IT,IAKUSHKIN VV,et al. Mean platelet volume:Interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels[J]. Biomed Khim,2014,60(1):94-108.
|
|
[8] BASARANOGLU M,NAJJAR SM,DEMIRBAG AE,et al. Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list[J]. World J Hepatol,2016,8(7):376-384.
|
|
[9] STEINBERG HO,BARON AD. Insulin-mediated vasodilation:Why one’s physiology could be the other’s pharmacology[J]. Diabetologia,1999,42(4):493-495.
|
|
[10] VERRIJKEN A,FRANCQUE S,MERTENS I,et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2014,59(1):121-129.
|
|
[11] LOMBARDI AM,FABRIS R,BERTI DE MARINIS G,et al. Defective adamts13 synthesis as a possible consequence of nash in an obese patient with recurrent thrombotic thrombocytopenic purpura[J]. Eur J Haematol,2014,92(6):497-501.
|
|
[12] TRIPODI A,FRACANZANI AL,PRIMIGNANI M,et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease[J]. J Hepatol,2014,61(1):148-154.
|
|
[13] KOTRONEN A,JOUTSI-KORHONEN L,SEVASTIANOVA K,et al. Increased coagulation factor VIII,IX,XI and XII activities in non-alcoholic fatty liver disease[J]. Liver Int,2011,31(2):176-183.
|
|
[14] CIGOLINI M,TARGHER G,AGOSTINO G,et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men-role of the metabolic syndrome[J]. Thromb Haemost,1996,76(1):69-73.
|
|
[15] TRIPODI A. Thrombin generation assay and its application in the clinical laboratory[J]. Clin Chem,2016,62(5):699-707.
|
|
[16] NORTHUP PG,ARGO CK,SHAH N,et al. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease:Mechanisms,human evidence,therapeutic implications,and preventive implications[J]. Semin Liver Dis,2012,32(1):39-48.
|
|
[17] BALTA G,ALTAY C,GURGEY A. Pai-1 gene 4g/5g genotype:A risk factor for thrombosis in vessels of internal organs[J]. Am J Hematol,2002,71(2):89-93.
|
|
[18] STINE JG,NORTHUP PG. Coagulopathy before and after liver transplantation:From the hepatic to the systemic circulatory systems[J]. Clin Liver Dis,2017,21(2):253-274.
|
|
[19] KILLEWICH LA,MACKO RF,MONTGOMERY PS,et al. Exercise training enhances endogenous fibrinolysis in peripheral arterial disease[J]. J Vasc Surg,2004,40(4):741-745.
|
|
[20] EL-SAYED MS,EL-SAYED ALI Z,AHMADIZAD S. Exercise and training effects on blood haemostasis in health and disease:An update[J]. Sports Med,2004,34(3):181-200.
|
|
[21] FRANCIS RM,ROMEYN CL,COUGHLIN AM,et al. Age and aerobic training status effects on plasma and skeletal muscle tpa and PAI-1[J]. Eur J Appl Physiol,2014,114(6):1229-1238.
|
|
[22] KUPCHAK BR,CREIGHTON BC,ARISTIZABAL JC,et al.Beneficial effects of habitual resistance exercise training on coagulation and fibrinolytic responses[J]. Thromb Res,2013,131(6):e227-e234.
|
|
[23] POLLOCK ML,FRANKLIN BA,BALADY GJ,et al. AHA science advisory. Resistance exercise in individuals with and without cardiovascular disease:Benefits, rationale, safety,and prescription:An advisory from the committee on exercise,rehabilitation,and prevention,council on clinical cardiology,american heart association; position paper endorsed by the american college of sports medicine[J]. Circulation,2000,101(7):828-833.
|
|
[24] SKURK T,HAUNER H. Obesity and impaired fibrinolysis:Role of adipose production of plasminogen activator inhibitor-1[J]. Int J Obes Relat Metab Disord,2004,28(11):1357-1364.
|
|
[25] CUI SB,SHU RH,YAN SP,et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol,2015,27(8):914-919.
|
|
[26] CHEN H,LIU L,QI X,et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol,2016,28(1):82-89.
|
|
[27] QI X,HAN G,FAN D. Management of portal vein thrombosis in liver cirrhosis[J]. Nat Rev Gastroenterol Hepatol,2014,11(7):435-446.
|
|
[28] QUILLIN RC 3rd,WILSON GC,SUTTON JM,et al. Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation[J]. Surgery,2014,156(4):1049-1056.
|
|
[29] PONZIANI FR,ZOCCO MA,SENZOLO M,et al. Portal vein thrombosis and liver transplantation:Implications for waiting list period,surgical approach,early and late follow-up[J].Transplant Rev(Orlando),2014,28(2):92-101.
|
|
[30] TARANTINO G,CITRO V,ESPOSITO P,et al. Blood ammonia levels in liver cirrhosis:A clue for the presence of portosystemic collateral veins[J]. BMC Gastroenterol,2009,9:21.
|
|
[31] ENGLESBE MJ,KUBUS J,MUHAMMAD W,et al. Portal vein thrombosis and survival in patients with cirrhosis[J]. Liver Transpl,2010,16(1):83-90.
|
|
[32] AYALA R,GRANDE S,BUSTELOS R,et al. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients[J]. BMC Gastroenterol,2012,12:114.
|
|
[33] GHABRIL M,AGARWAL S,LACERDA M,et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation:Analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients[J]. Transplantation,2016,100(1):126-133.
|
|
[34] SUAREZ ARTACHO G,BARRERA PULIDO L,ALAMO MARTINEZ JM,et al. Outcomes of liver transplantation in candidates with portal vein thrombosis[J]. Transplant Proc,2010,42(8):3156-3158.
|
|
[35] KARVELLAS CJ,CARDOSO FS,SENZOLO M,et al. Clinical impact of portal vein thrombosis prior to liver transplantation:A retrospective cohort study[J]. Ann Hepatol,2017,16(2):236-436.
|
|
[36] BERTELLI R,NARDO B,MONTALTI R,et al. Liver transplantation in recipients with portal vein thrombosis:Experience of a single transplant center[J]. Transplant Proc,2005,37(2):1119-1121.
|
|
[37] PAN C,SHI Y,ZHANG JJ,et al. Single-center experience of253 portal vein thrombosis patients undergoing liver transplantation in China[J]. Transplant Proc,2009,41(9):3761-3765.
|
|
[38] AGBIM U,JIANG Y,KEDIA SK,et al. Impact of nonmalignant portal vein thrombosis in transplant recipients with nonalcoholic steatohepatitis[J]. Liver Transpl,2019,25(1):68-78.
|
DownLoad: